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Outcomes After Being Lost to Follow-up Differ for Pregnant
and Postpartum Women When Compared With the
General HIV Treatment Population in Rural South Africa
David Etoori, MPH,a Francesc Xavier Gomez-Olive, PhD,b Georges Reniers, PhD,a,b Brian Rice, PhD,c
Jenny Renju, PhD,a,d Chodziwadziwa W. Kabudula, PhD,b and Alison Wringe, PhDa
Background: Undetermined attrition prohibits full understanding of
the coverage and effectiveness of HIV programs. Outcomes following
loss to follow-up (LTFU) among antiretroviral therapy (ART) patients
may differ according to their reasons for ART initiation.
Setting: We compare the true outcomes of adult patients previously
identified as LTFU by reason for ART initiation in 8 health facilities
in north eastern South Africa.
Methods: Adult HIV patient records were linked to health and
demographic surveillance system (HDSS) data from 2014 to 2017.
Outcomes of adults categorized as LTFU (.90 days late for the last
scheduled clinic visit) were determined through clinic and routine
tracing record reviews, consultation of HDSS data, and supplemen-
tary tracing. We calculated the proportion of patients per outcome
category and performed competing risk survival analysis to estimate
the cumulative incidence of death, transfer, migration, ART
interruption, and re-engagement following LTFU.
Results: Of 895/1017 patients LTFU with an outcome ascertained,
120 (13.4%) had died, 225 (25.1%) re-engaged, 50 (5.6%) migrated
out of the HDSS, 75 (8.4%) were alive and not on treatment, and 315
(35.1%) transferred their treatment. These outcomes varied by sex
and pregnancy status at ART initiation. Mortality was less likely
among pregnant women, patients with higher baseline CD4, and
more likely among older patients.
Conclusions: Patient survival and transfers to other facilities are
considerably higher than those suggested in earlier studies. Out-
comes differ for women who were pregnant or postpartum when
initiating ART, with this population less likely to have died and more
likely to have migrated.
Key Words: HIV, lost to follow-up, mother-to-child transmission,
South Africa, patient outcome assessment, retention
(J Acquir Immune Defic Syndr 2020;85:127–137)
INTRODUCTION
As HIV programs in sub-Saharan Africa have
expanded, emphasis has been put on initiating patients on
antiretroviral therapy (ART) as early as possible in the course
of HIV infection.1,2 Eligibility for ART has changed since the
adoption of Option B+ which made all pregnant and post-
partum women eligible for ART as soon as they tested HIV
positive and “Treat all” which extended this eligibility to all
people living with HIV.3 Although ART initiation rates
among people diagnosed with HIV have increased,4–6 many
programs have experienced high attrition rates, especially
among women who initiate ART for prevention of mother-to-
child transmission of HIV (PMTCT).7 Many of these patients
are classified as lost to follow-up (LTFU), a general term for
unknown outcomes of patients who have not returned for
a scheduled clinic visit. LTFU is often an amalgamation of
“silent” (undocumented) clinic transfers, treatment interrup-
tions or stoppages, and deaths,8–12 which are challenging to
accurately document using routine reporting mechanism.13–15
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Misclassification of patients as being LTFU can lead to
as much as a five-fold underestimation of retention and
deaths.16 Understanding true outcomes among patients who
are reported as LTFU is important to accurately monitor and
report on indicators for national ART programs and better
target tracing efforts.10 Accurate mortality estimates are also
important for parameterizing epidemic projections in software
programs such as the UNAIDS Spectrum package.17
A systematic review of HIV patient tracing studies
conducted in sub-Saharan Africa from 2001 to 2012 reported
that 39% of patients documented as LTFU in clinic records
had died, 18.6% had self-transferred to other HIV clinics, and
28.6% had stopped ART but were still alive.12 An earlier
review covering studies in sub-Saharan Africa undertaken
between 2004 and 2008 reported that 42% of patients
documented as LTFU in HIV clinics had died.18
These 2 reviews were conducted in the earlier stages of
sub-Saharan African ART programs when ART patient
profiles included a higher proportion with severe immuno-
suppression at treatment initiation and before universal ART
for HIV-positive pregnant women (Option B+) had been
introduced.19 In addition, decentralization of ART programs
means ART can be provided closer to patients’ homes,12
which may have increased the number of “silent” transfers
taking place within these programs. Furthermore, the pro-
portion of pregnant and postpartum women in ART programs
has increased since the adoption of Option B+. This
population differs from the general adult population on
ART in several ways that are likely to affect the true
outcomes among those LTFU, yet few studies have traced
women LTFU from PMTCT programs.20 First, ART initia-
tion eligibility criteria for pregnant women have included
higher CD4 counts in many settings over the past decade,
such that on average they are more likely to initiate treatment
while still asymptomatic.21 In addition, childbirth is a risk
factor for default from treatment programs22,23 for reasons
including postpartum depression or out-referral from PMTCT
programs after delivery.24–26
With recent randomized control trials of universal test
and treat showing modest and mixed results regarding
reducing HIV incidence,27–29 it is imperative that we
understand outcomes among nonadherent patients including
those LTFU. This will help to develop and direct innovative
ways to identify and reach those who have truly disengaged
from care. In this context, we conducted a tracing study in
Agincourt in rural north-eastern South Africa to ascertain the
true outcomes of patients who were LTFU, disaggregated by
whether they were pregnant or postpartum when initiating
ART (PMTCT) or not, to better understand the outcomes of
this group and compare them to the adult ART population
who met other criteria for ART initiation.
METHODS
Setting
The Agincourt Health and Demographic Surveillance
System (HDSS) is located in Mpumalanga province in rural
north-eastern South Africa. Established in 1992, the site is
approximately 475 square kilometers and has conducted
annual demographic surveys within the HDSS population to
capture births, deaths, and migrations since 1999.30,31 In
2013, HIV prevalence in the HDSS population aged 15 years
or older was estimated at 19.4%32
The HDSS also collects verbal autopsy (VA) data to
ascertain probable causes of death.33 In brief, a structured
interview was conducted with people who were closely
related to or cared for the deceased during the final illness
and could report on symptoms and signs they observed during
this period. The interview was conducted using a locally
validated tool, in the local language. Until 2010, 2 medical
doctors independently reviewed the data to assign a cause of
death based on international classification of diseases (ICD-
10) conventions,34 with a third doctor used in the event of
a lack of consensus. The cause was coded “undetermined” if
this failed to yield any agreement.30,35 Since 2011, causes of
death are assigned using the InterVA-4 probabilistic model.36
There are 5 primary health facilities and 3 secondary
community health centers located within the Agincourt
HDSS, all of which offer HIV services including testing
and treatment. All health facilities routinely trace patients that
are late for a scheduled appointment, with some clinics
receiving tracing support from 2 nonprofit organizations,
Right-to-Care (RtC) (6 facilities) and Home-Based Carers
(HBC) (7 facilities). Routine tracing is described in detail
elsewhere.37 Briefly, tracing procedures are triggered once
a patient is more than 5 working days late for a scheduled
visit and usually involves 2 steps, 3 phone calls, and a home
visit if the phone calls do not yield a satisfactory outcome.
Patients are considered LTFU if they have not returned to the
clinic 90 days after their scheduled visit.
In 2014, an initiative was started to identify registered
HDSS residents when they visited local health facilities. The
point-of-contact interactive record linkage (PIRL) matches
chronic care (HIV, diabetic and hypertensive) patient informa-
tion at the health facility to their HDSS record. This is done in
the presence of the patient to resolve any indecision about their
identity in the event of multiple resident matches.38
Record Review and Tracing Study
Using the PIRL database, we identified patients who
were more than 90 days late for a scheduled HIV clinic
appointment on August 15, 2017 at any of the 8 health
facilities located in the Agincourt HDSS. Patients were
included in the cohort if they were 18 years or older, had
ever declared residency in the HDSS, and had enrolled in HIV
treatment after PIRL was established at the health facilities.
Patients who had not yet initiated ART were excluded
from our analyses because they did not have a next scheduled
visit and as such it was impossible to determine whether they
were LTFU or just visited the clinics less frequently. Further-
more, this population would not be comparable to patients who
had potentially accrued some benefits from taking ART.
Patients were followed up to ascertain whether they
were still alive and still on treatment. Trained fieldworkers
conducted a thorough record review, on a case-by-case basis,
to resolve each patient outcome by comparing the list of
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patients LTFU against (1) TIER.Net (the electronic medical
records database for health facilities in South Africa)39 (2)
paper-based patient clinic files, and (3) logbooks kept by RtC
and HBC. The PIRL database was also reviewed for duplicate
patients who were then considered silent transfers. Residency
and vital status were also checked in the HDSS demographic
surveillance database.
Home-Based Carers conducted a further home visit for
all patients without an outcome resolution (ie, no definitive
outcome after the record review and for whom routine tracing
had not previously been done). For all patients remaining
LTFU, searches were undertaken in TIER.Net databases of
clinics in close proximity to their residence to capture any
further silent transfers (see Supplementary Figure 1, Supple-
mental Digital Content, http://links.lww.com/QAI/B486).
Definitions
A patient was considered to have died if they were
reported as deceased in their patient file or in TIER.Net or if
they were reported to have died through HDSS
surveillance data.
A patient was considered to have re-engaged in care if
they were found to still be in care at the same clinic where
they initiated treatment but were .90 days late for their
last appointment.
A patient was defined as having transferred if they had
either reported taking treatment at another clinic, if the clinic
at which they initiated ART had communicated with and
ascertained their transfer to another clinic, or if there was
a record of them collecting treatment from another clinic
within the Agincourt HDSS.
Patients were defined as having migrated if they were
recorded as such (movement outside the study area) through
the HDSS, the migration event happened after their last clinic
visit and there was no evidence of them taking treatment at
another clinic.
A patient had stopped ART if they had been found and
reported that they stopped ART, denied their HIV status or
refused to return to the clinic.
A patient was alive with ART status unknown if
additional tracing yielded no definitive outcome, but they
were found to still be alive through the most recent
demographic surveillance round, with a surveillance date
after their last clinic visit.
A data error was a situation where a patient was ,90
days late for their next scheduled appointment but was
erroneously classified as LTFU.
Statistical Analyses
Counts and proportions were calculated for socio-
demographic, baseline clinical characteristics, patient tracing
outcomes, and VA causes of death. A Pearson’s x2 test was
used to compare categorical variables.
Competing risk survival analysis methods were used to
estimate the cumulative incidence of death, transfer, migra-
tion, ART stoppage, and re-engagement following loss to
follow-up (LTFU). Follow-up time began on the date of each
patient’s last recorded clinic visit as we suspected that some
outcomes especially deaths would occur closely following
a last visit and before patients would have been categorized as
LTFU. Using these cumulative probabilities, status plots were
produced stratified by sex, pregnancy status at ART initiation,
and baseline CD4.
A Cox regression model was used to determine the
factors associated with death, with all other outcomes
considered to be right-censored. Bivariate analyses were
conducted with a priori selected variables that had been
shown to be associated with death in previous studies.18,40–42
All variables with P , 0.1 were included in the multivariable
Cox regression model. A parsimonious model was achieved
using Wald tests. All analyses were conducted using Stata
15.43 All models accounted for clustering at the clinic level
and used robust standard errors.
Ethics
Ethical approval was obtained from the London School
of Hygiene and Tropical Medicine, the University of
Witwatersrand, and the Mpumalanga Department of Health.
RESULTS
Population Characteristics
Over the study period, 4089 patients were added to the
PIRL database and met the inclusion criteria. Of these 4089,
1325 (32.4%) met the LTFU criteria and were eligible for
inclusion in the record review and tracing study. Of these
1325 patients, 166 (12.5%) did not have an ART initiation
date. Further investigation of these 166 patients found 46
(27.7%) had initiated ART after record linkage, 59 (35.5%)
had not yet initiated ART, and 61 (36.7%) had initiated ART
before record linkage began. These 61 patients and the 59
non-ART patients were excluded from further analyses. Of
the remaining 1205 patients, 188 (15.6%) were misclassified
as LTFU due to data errors (missed clinic visits in the PIRL
database) and were excluded from further analysis (see
Supplementary Figure 2, Supplemental Digital Content,
http://links.lww.com/QAI/B486). Analyses of these 188 pa-
tients to evaluate the utility of routine tracing are presented in
supplementary information (see Supplementary information
1, Supplemental Digital Content, http://links.lww.com/QAI/
B486). The remaining 1017 patients were 91–1188 days late
(see Supplementary Figure 3, Supplemental Digital Content,
http://links.lww.com/QAI/B486).
Of the 1017 remaining patients, 280 (27.5%) initiated
ART for PMTCT, 767 (75.4%) were women and 849 (83.5%)
linked to an HDSS record (Table 1). Pregnant women were
younger with a median age of 29 years (IQR: 25, 33)
compared with nonpregnant women, 33 years (IQR: 28, 42)
and men, 41 years (IQR: 34, 48). Of 280 patients who
initiated ART for PMTCT, 52 (18.6%) had a baseline CD4
,200 cells/mL compared with 193 of 487 (39.6%) non-
pregnant women and 146 of 250 (58.4%) men. None of the
patients who initiated ART for PMTCT with baseline CD4
,200 cells/mL were categorized as WHO stage III/IV
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compared with 53 of 193 (27.5%) nonpregnant women and
45 of 146 (30.8%) men. Furthermore, 5.0% of women who
initiated treatment for PMTCT had a CD4 less than 100 cells/
mL compared with 21.8% of nonpregnant women and 34.4%
of men. The main reason for ART initiation for nonpregnant
patients was CD4 count criteria (74.5%) (Table 1).
Sources of Resolution
Of the 1017 patients LTFU, 895 (88.0%) were resolved,
with 536 (59.9%) of these occurring through record review,
155 (17.3%) through demographic surveillance data (23
migrations, 21 deaths, 111 alive), 72 (8.0%) through sub-
sequent visit data in the PIRL database, 53 (5.9%) through
supplementary tracing, 57 (6.4%) identified as duplicates in
the PIRL database (one person matching to multiple clinic
records), and 22 (2.5%) through a search of patient records in
clinics in close proximity to the patient’s residence.
Patient Outcomes
Of 1017 patients LTFU, 120 [11.8%, 95% confidence
interval (CI): 9.9 to 13.9] had died, 315 (31.0%, CI: 28.1 to
33.9) had transferred to another facility, 75 (7.4%, CI: 5.8 to
9.1) had stopped ART, 49 (4.8%, CI: 3.6 to 6.3) had
migrated, 225 (22.1%, CI: 19.6 to 24.8) re-engaged in care,
111 (10.9%, CI: 9.1 to 13.0) were alive with an unknown
treatment status, and 122 (12.0%) remained LTFU. These
TABLE 1. Patient Demographic and Clinical Characteristics,







1017 280 487 250
N (%) N (%) N (%) N (%)
Age
18–29 333 (32.7) 150 (53.6) 157 (32.2) 26 (10.4)
30–44 484 (47.6) 124 (44.3) 226 (46.4) 134 (53.6)
45–59 141 (13.9) 6 (2.1) 70 (14.4) 65 (26.0)
60+ 58 (5.7) 0 (0) 33 (6.8) 25 (10.0)
Missing 1 (0.1) 0 (0) 1 (0.2) 0 (0)
ART reason
CD4 549 (54.0) 0 (0) 376 (77.2) 173 (69.2)
PMTCT 280 (27.5) 280 (100.0) 0 (0) 0 (0)
WHO Stage 77 (7.6) 0 (0) 45 (9.2) 32 (12.8)
Test and treat 43 (4.2) 0 (0) 23 (4.7) 20 (8.0)
TB 39 (3.8) 0 (0) 17 (3.5) 22 (8.8)
Missing 29 (2.9) 0 (0) 26 (5.3) 3 (1.2)
ART start yr
2014 211 (20.8) 58 (20.7) 101 (20.7) 52 (20.8)
2015 414 (40.7) 105 (37.5) 212 (43.5) 97 (38.8)
2016 350 (34.4) 107 (38.2) 157 (32.2) 86 (34.4)
2017 42 (4.1) 10 (3.6) 17 (3.5) 15 (6.0)
Time on ART
#3 mo 325 (32.0) 89 (31.8) 136 (27.9) 100 (40.0)
3–6 mo 190 (18.7) 70 (25.0) 88 (18.1) 32 (12.8)
6–12 mo 228 (22.4) 70 (25.0) 114 (23.4) 44 (17.6)
12–24 mo 219 (21.5) 39 (13.9) 120 (24.6) 60 (24.0)
.24 mo 55 (5.4) 12 (4.3) 29 (6.0) 14 (5.6)
Baseline CD4
,100 206 (20.2) 14 (5.0) 106 (21.8) 86 (34.4)
100–199 185 (18.2) 38 (13.6) 87 (17.9) 60 (24.0)
200–349 261 (25.7) 71 (25.4) 129 (26.5) 61 (24.4)
350–499 193 (19.0) 74 (26.4) 95 (19.5) 24 (9.6)
500+ 145 (14.3) 64 (22.9) 64 (13.1) 17 (6.8)
Missing 27 (2.6) 19 (6.8) 6 (1.2) 2 (0.8)
Baseline WHO
stage
I 722 (71.9) 261 (93.2) 329 (67.6) 132 (52.8)
II 143 (14.1) 17 (6.1) 73 (15.0) 53 (21.2)
III 129 (12.7) 2 (0.7) 70 (14.4) 57 (22.8)
IV 10 (1.0) 0 (0) 6 (1.2) 4 (1.6)
Missing 13 (1.3) 0 (0) 9 (1.8) 4 (1.6)
Refill schedule
1 mo 672 (66.1) 188 (67.1) 322 (66.1) 162 (64.8)
2 mo 233 (22.9) 68 (24.3) 102 (20.9) 63 (25.2)
3 mo 79 (7.8) 20 (7.1) 44 (9.0) 15 (6.0)
.3 mo 33 (3.2) 4 (1.4) 19 (3.9) 10 (4.0)
Health facility
Agincourt 272 (26.7) 74 (26.4) 141 (28.9) 57 (22.8)
Belfast 186 (18.3) 64 (22.9) 80 (16.4) 42 (16.8)
Cunningmore 58 (5.7) 16 (5.7) 32 (6.6) 10 (4.0)
Justicia 120 (11.8) 42 (15.0) 42 (8.6) 36 (14.4)
Kildare 117 (11.5) 25 (8.9) 62 (12.7) 30 (12.0)
Lillydale 166 (16.3) 32 (11.4) 81 (16.6) 53 (21.2)
TABLE 1. (Continued ) Patient Demographic and Clinical
Characteristics, and Final Outcomes Disaggregated by






1017 280 487 250
N (%) N (%) N (%) N (%)
Thulamahashe 25 (2.5) 9 (3.2) 12 (2.5) 4 (1.6)
Xanthia 73 (7.2) 18 (6.4) 32 (7.6) 18 (7.2)
Time since last
appointment
#1 yr 526 (51.7) 130 (46.4) 255 (52.4) 141 (56.4)
1–2 yrs 369 (36.3) 117 (41.8) 176 (36.1) 76 (30.4)
.2 yrs 122 (12.0) 33 (11.8) 56 (11.5) 33 (13.2)
AHDSS outcome
Still in HDSS 505 (49.7) 142 (50.7) 237 (48.7) 126 (50.4)
Deceased 74 (7.3) 6 (2.1) 42 (8.6) 26 (10.4)
Migrated 270 (26.5) 99 (35.4) 125 (25.7) 46 (18.4)
Not linked 168 (16.5) 33 (11.8) 83 (17.0) 52 (20.8)
Final outcome
Deceased 120 (11.8) 10 (3.6) 60 (12.3) 50 (20.0)
Transferred out 315 (31.0) 82 (29.3) 176 (36.1) 57 (22.8)
Stopped ART 75 (7.4) 28 (10.0) 20 (4.1) 27 (10.8)
Migrated 49 (4.8) 21 (7.5) 22 (4.5) 6 (2.4)
Reengaged 225 (22.1) 54 (19.3) 110 (22.6) 61 (24.4)
Alive: ART
unknown
111 (10.9) 45 (16.1) 45 (9.2) 21 (8.4)
LTFU 122 (12.0) 40 (14.3) 54 (11.1) 28 (11.2)
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outcomes differed (all P , 0.001) by sex, age, baseline CD4
count, time on ART, clinic visit schedule, health facility, time
since a missed appointment, and ART initiation reason.
Women who initiated treatment while pregnant or postpartum
were less likely to have died [3.6% (CI: 1.7 to 6.5) compared
with 14.9% (CI: 12.4 to 17.7)] and more likely to have
migrated [7.5% (CI: 4.7 to 11.2) compared with 3.8% (CI: 2.5
to 5.4)], to be alive with their ART status unknown [16.1%
(CI: 12.0 to 20.9) compared with 8.9% (CI: 7.0 to 11.2)] or
stopped ART [10.0% (CI: 6.7 to 14.1) compared with 6.4%
(CI: 4.7 to 8.4)] (Table 2).
Most deaths occurred in the groups where baseline CD4
,200 cells/mL (Figure 1). Men were at highest risk of
mortality, and pregnant women were at the lowest risk (Figure
2). Men and pregnant women also had higher risks of being
alive and not in care compared with nonpregnant women
(Figure 2). The mortality risk appeared to be similar for all
CD4 categories for pregnant women unlike for nonpregnant
women (see Supplementary Figure 4 and 5, Supplemental
Digital Content, http://links.lww.com/QAI/B486). We also
report on probable causes of death ascertained using VA data
(see Supplementary information 2, Supplemental Digital
Content, http://links.lww.com/QAI/B486).
Factors Associated With Death
Of 120 deaths, 48 (37.2%) occurred before the patient’s
next visit date, 42 (32.6%) occurred after the patient's next
scheduled visit date but before they would have met the criteria
for LTFU, 30 (23.3%) occurred after the patient had met the
criteria for LTFU, and 9 (7.0%) had a missing date of death.
In multivariable competing risk regression, being preg-
nant at ART initiation (aHR: 0.36, 95% CI: 0.15 to 0.87), and
longer time on ART (12–24 months aHR: 0.44, 0.23 to 0.85)
were associated with lower hazard of death following LTFU.
Older age ($60 years aHR: 8.86, 3.90–20.14) and lower CD4
at ART initiation (,100 cells/mL aHR: 3.77, 2.31–6.15;
100–199 cells/mL aHR: 2.35, 1.49–3.69) were associated with
a higher hazard of death (Table 3).
DISCUSSION
We describe the treatment outcomes of HIV patients
enrolled in care between April 2014 and August 2017 who
had become LTFU in a rural South African setting as
determined through a comprehensive record review and
tracing study. Using multiple data sources and methods, we
managed to ascertain the outcomes of 88% of the patients
LTFU, a figure that is higher than most studies included in
a recent systematic review of tracing studies in sub-Saharan
Africa.12 We found that 31% of patients LTFU had trans-
ferred to another facility, 22% had re-engaged in care, and
12% of patients had died. These percentages varied by sex,
reason for ART initiation, and baseline CD4 cell count. The
differences for pregnant and postpartum women are particu-
larly pertinent given that they represent the first iterations of
treatment as prevention and could provide an indication for
what to expect with the move to test and treat for all people
living with HIV.
The proportion of patients reported as LTFU who had
died in our study was substantially lower than the 42% and
39% reported in earlier systematic reviews of tracing studies
from sub-Saharan Africa.12,18 Even if all the patients remain-
ing LTFU after record review and tracing had died, mortality
in our study would only rise to 24%. This lower percentage of
deaths compared with the previous reviews is likely to be
because of a healthier cohort of patients initiating treatment.
We found that pregnant women were less likely to have died,
an encouraging trend if it does translate to the general ART
treatment population as less immunocompromised people
begin to initiate ART. Mortality following LTFU may
decrease further as universal test and treat policies result in
growing proportions of asymptomatic patients initiating ART.
In competing risk survival analysis, being pregnant at
ART initiation, higher baseline CD4, and longer time on ART
were protective against death, whereas older age was found to
be associated with a higher hazard of death following LTFU.
Our findings suggest baseline CD4 cell count, WHO stage,
and older age remain accurate measures for determining
which patients are at highest risk for death,42,44,45 and these
characteristics could be used to help prioritize tracing
interventions. Whereas mortality risk appeared to wane with
increasing CD4 at baseline for nonpregnant women and men,
mortality appeared to be similar for all CD4 categories for
women who initiated treatment for PMTCT. This may reflect
the fact that their mortality risk was more influenced by other
factors such as pregnancy related complications than by
HIV.46,47 This could also be because of the fact that pregnant
women were healthier in WHO staging compared with
nonpregnant women and men, given the same CD4 at
baseline, also reflected by the lower proportion of pregnant
patients with a baseline CD4,100 cells/mL. This discrepancy
could also be related to temporary declines in CD4 count
during pregnancy.48
Patients lost early on in treatment were at higher risk of
death and this remained statistically significant even when
controlling for baseline CD4, indicating that a longer duration
on ART before attrition may reduce the risk of death. This
protective effect appeared to be strongest for those who had
been on ART 12–24 months before they became LTFU. This
suggests that in settings with limited resources, tracing should
be considered most urgent for newly ART-initiated patients
who drop out of care. On the other hand, it may also indicate
that some patients are still initiating treatment too late. In this
study, 11% of nonpregnant patients had a CD4 cell count
.500 cells/mL (compared with 23% of pregnant women),
reflecting the fact that universal test and treat was not adopted
in South Africa until September 2016.49,50 Men were
disproportionately over-represented in the ,200 cells/mL
baseline CD4 category despite South African guidelines for
ART initiation with CD4 ,500 cells/mL having been in effect
since January 2015.51 Men especially appear to be harder to
reach and come into care later, similar to findings from other
studies,52–55 and emphasizes the need to reach men earlier
with ART.56–58
However, as the proportion of LTFU attributable to
mortality dwindles, other outcomes are likely to become more
prevalent. In our study, transfer to another facility accounted
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TABLE 2. Patient Outcomes Disaggregated by Patient Demographic and Clinical Characteristics
Outcome Total
Deceased Transferred out Stopped ART Migrated Reengaged Alive: ART unknown Still LTFU All LTFU
120 315 75 49 225 111 122 1017
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Sex (P , 0.001)
Female 70 (9.1) 258 (33.6) 48 (6.3) 43 (5.6) 164 (21.4) 90 (11.7) 94 (12.2) 767 (75.4)
Male 50 (20.0) 57 (22.8) 27 (10.8) 6 (2.4) 61 (24.4) 21 (8.4) 28 (11.2) 250 (24.6)
Age (P , 0.001)
18–29 17 (5.1) 117 (35.1) 24 (7.2) 25 (7.5) 61 (18.3) 46 (13.8) 43 (12.9) 333 (32.7)
30–44 55 (11.4) 147 (30.4) 37 (7.6) 21 (4.3) 116 (24.0) 50 (10.3) 58 (12.0) 484 (47.6)
45–59 27 (19.1) 38 (26.9) 11 (7.8) 2 (1.4) 35 (24.8) 13 (9.2) 15 (10.6) 141 (13.9)
60+ 21 (36.2) 13 (22.4) 3 (5.2) 1 (1.7) 12 (20.7) 2 (3.4) 6 (10.3) 58 (5.7)
Missing 0 (0) 0 (0) 0 (0) 0 (0) 1 (100) 0 (0) 0 (0) 1 (0.1)
ART reason (P , 0.001)
Non-PMTCT 110 (14.9) 233 (31.6) 47 (6.4) 28 (3.8) 171 (23.2) 66 (8.9) 82 (11.1) 737 (72.5)
PMTCT 10 (3.6) 82 (29.3) 28 (10.0) 21 (7.5) 54 (19.3) 45 (16.1) 40 (14.3) 280 (27.5)
ART start yr (P = 0.251)
2014 28 (13.3) 58 (27.5) 14 (6.6) 18 (8.5) 50 (23.7) 19 (9.0) 24 (11.4) 211 (20.7)
2015 41 (9.9) 149 (36.0) 33 (8.0) 16 (3.9) 82 (19.8) 44 (10.6) 49 (11.8) 414 (40.7)
2016 46 (13.1) 100 (28.6) 24 (6.9) 14 (4.0) 82 (23.4) 41 (11.7) 43 (12.3) 350 (34.4)
2017 5 (11.9) 8 (19.0) 4 (9.5) 1 (2.4) 11 (26.2) 7 (16.7) 6 (14.3) 42 (4.1)
Time on ART (P , 0.001)
#3 mo 54 (16.6) 89 (27.3) 29 (8.9) 13 (4.0) 47 (14.5) 41 (12.6) 52 (16.0) 325 (32.0)
3–6 mo 18 (9.5) 62 (32.6) 13 (6.8) 8 (4.2) 31 (16.3) 30 (15.8) 28 (14.7) 190 (18.7)
6–12 mo 25 (11.0) 79 (34.6) 12 (5.3) 17 (7.5) 42 (18.4) 25 (11.0) 28 (12.3) 228 (22.4)
12–24 mo 16 (7.3) 76 (34.7) 17 (7.8) 9 (4.1) 75 (34.2) 13 (5.9) 13 (5.9) 219 (21.5)
.24 mo 7 (12.7) 9 (16.4) 4 (7.3) 2 (3.6) 30 (54.5) 2 (3.6) 1 (1.8) 55 (5.4)
Baseline CD4 (P , 0.001)
,100 50 (24.3) 64 (31.1) 8 (3.9) 4 (1.9) 38 (18.4) 13 (6.3) 29 (14.1) 206 (20.2)
100–199 32 (17.3) 46 (24.9) 16 (8.6) 8 (4.3) 41 (22.2) 19 (10.3) 23 (12.4) 185 (18.2)
200–349 19 (7.3) 69 (26.4) 23 (8.8) 12 (4.6) 63 (24.1) 43 (16.5) 32 (12.3) 261 (25.7)
350–499 11 (5.7) 72 (37.3) 16 (8.3) 14 (7.3) 36 (18.6) 20 (10.4) 24 (12.4) 193 (19.0)
500+ 8 (5.5) 53 (36.5) 11 (7.6) 10 (6.9) 41 (28.3) 12 (8.3) 10 (6.9) 145 (14.3)
Missing 0 (0) 11 (40.7) 1 (3.7) 1 (3.7) 6 (22.2) 4 (14.8) 4 (14.8) 27 (2.6)
Baseline WHO stage (P = 0.017)
I 65 (9.0) 230 (31.8) 55 (7.6) 38 (5.3) 159 (22.0) 88 (12.2) 87 (12.0) 722 (71.0)
II 21 (14.7) 42 (29.4) 12 (8.4) 6 (4.2) 34 (23.8) 11 (7.7) 17 (11.9) 143 (14.1)
III 26 (20.1) 39 (30.2) 7 (5.4) 4 (3.1) 28 (21.7) 9 (7.0) 16 (12.4) 129 (12.7)
IV 5 (50.0) 1 (10.0) 1 (10.0) 0 (0) 2 (20.0) 0 (0) 1 (10.0) 10 (1.0)
Missing 3 (23.1) 3 (23.1) 0 (0) 1 (7.7) 2 (15.4) 3 (23.1) 1 (7.7) 13 (1.3)
Refill schedule (P , 0.001)
1 mo 84 (12.5) 210 (31.2) 48 (7.1) 30 (4.5) 143 (21.3) 77 (11.4) 80 (11.9) 672 (66.1)
2 mo 24 (10.3) 71 (30.5) 21 (9.0) 14 (6.0) 43 (18.4) 24 (10.3) 36 (15.5) 233 (22.9)
3 mo 9 (11.4) 30 (38.0) 3 (3.8) 5 (6.3) 18 (22.8) 9 (11.4) 5 (6.3) 79 (7.8)
.3 mo 3 (9.1) 4 (12.1) 3 (9.1) 0 (0) 21 (63.6) 1 (3.0) 1 (3.0) 33 (3.2)
Health facility (P , 0.001)
Agincourt 27 (9.9) 66 (24.3) 15 (5.5) 11 (4.0) 110 (37.1) 21 (7.7) 22 (8.1) 272 (26.7)
Belfast 16 (8.6) 52 (28.0) 13 (7.0) 12 (6.4) 32 (17.2) 29 (15.6) 32 (17.2) 186 (18.3)
Cunningmore 11 (19.0) 21 (36.2) 8 (13.8) 1 (1.7) 7 (12.1) 5 (8.6) 5 (8.6) 58 (5.7)
Justicia 20 (16.7) 30 (25.0) 13 (10.8) 7 (5.8) 14 (11.7) 11 (9.2) 25 (20.8) 120 (11.8)
Kildare 16 (13.7) 50 (42.7) 10 (8.5) 8 (6.8) 14 (12.0) 9 (7.7) 10 (8.5) 117 (11.5)
Lillydale 19 (11.4) 51 (30.7) 9 (5.4) 7 (4.2) 37 (22.3) 24 (14.5) 19 (11.4) 166 (16.3)
Thulamahashe 3 (12.0) 4 (16.0) 1 (4.0) 0 (0) 7 (28.0) 6 (24.0) 4 (16.0) 25 (2.4)
Xanthia 9 (12.2) 41 (55.4) 6 (8.1) 3 (4.0) 4 (5.4) 6 (8.1) 5 (6.8) 74 (7.3)
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for 31% of patients who were reported as LTFU, which is
higher than a previous systematic review.12 Other studies
have suggested transfers become more common as programs
expand and offer ART closer to patients’ homes.12,59,60
Women were more likely to have transferred their care to
another clinic. For pregnant women, this could reflect the
higher mobility common during pregnancy and child-
birth.13,61,62 Furthermore, given that most of these transfers
were not reported to the sending facility similar to previous
studies,12,15 these types of transfers could potentially lead to
the spread of drug resistance in situations where ART
experienced patients are offered regimens that have lost any
therapeutic value due to drug resistance.63 Silent transfers
may also lead to over-estimates of the number of people
newly initiating ART and the number of people who have
ever initiated ART. The current system of transferring
patients could be improved by better referral systems, patient
education, regular information exchange between clinics, and
provider training.64
We found that 7.4% of patients had stopped treatment,
with this being more common for women who initiated ART
while pregnant, which adds to findings from previous studies
that suggest that feeling healthy contributes to attrition for
pregnant women.65,66 This figure is lower than the 28.6% of
treatment interruptions reported in a recent systematic
review.12 This may suggest that interventions to reduce
interruptions, including routine tracing, are working well in
this setting, further supported by the number of re-
engagements in care that were observed in our study.
Our data showed that pregnant women and the general
treatment cohort still differ significantly especially regarding
immune system markers such as CD4. However, with the
advent of test and treat, these groups may increasingly
become similar in this regard and hence outcomes for
pregnant women living with HIV could represent what
treatment programs may expect to see in the future regarding
patients that become LTFU especially those of a similar age.
With ART programs in sub-Saharan Africa maturing, and
with less immunologically compromised patients initiating
ART, patients that become LTFU will be less likely to have
died, whereas ART cessation or interruption and re-
engagement in care are likely to become more common.
Treatment programs will increasingly need to reallocate
resources to deal with improving the clinic transfer process
and invest in tracing and psychosocial support to get patients
back in care or else risk having high community viral load
which may increase the probability of onward transmission.
We showed that 6% of patients who were late for a scheduled
appointment returned before they officially became catego-
rized as LTFU. These patients in theory would have received
the routine tracing intervention offering further evidence of its
utility, in line with a previous study that has highlighted how
early active tracing of patients LTFU may improve patient
outcomes and retention in care.8
Furthermore, given that most resolutions came through
record review of tracing logbooks and clinic records, this
study demonstrates that routine patient tracing still has utility
for improving the completeness and accuracy of patient
records. The availability of these data within the clinics
suggests that routinely-collected data, especially those from
the 2 organizations that assist in patient tracing needs to be
better collated, integrated and recorded to ensure that patient
outcomes are reflected in their clinic files and on TIER.Net.
This study also demonstrates the utility of other data sources
such as HDSS data. Given the push to integrate national ID
numbers in patient profiles, clinics operating within similar
health and demographic surveillance sites should consider
liaising with these sites to improve the capture of deaths and
migrations. Policy makers should also consider using South
Africa’s national death registry within clinics as this has been
shown to be useful in other studies.67,68
This study had several limitations. First, the record
review was cross-sectional; we only consulted clinic records
at one point in time, whereas, some of these records may have
subsequently been updated. Furthermore, we only consulted
HBC and RtC logbooks that were afforded to us and it is
TABLE 2. (Continued ) Patient Outcomes Disaggregated by Patient Demographic and Clinical Characteristics
Outcome Total
Deceased Transferred out Stopped ART Migrated Reengaged Alive: ART unknown Still LTFU All LTFU
120 315 75 49 225 111 122 1017
N (%) N (%) N (%) N (%) N (%) N (%) N (%)
Time since last appointment
(P , 0.001)
#1 yr 48 (9.1) 146 (27.8) 40 (7.6) 16 (3.0) 171 (32.5) 51 (9.7) 54 (10.3) 526 (51.7)
1–2 yrs 53 (14.4) 134 (36.3) 26 (7.0) 19 (5.1) 46 (12.5) 44 (11.9) 47 (12.7) 369 (36.3)
.2 yrs 19 (15.6) 35 (28.7) 9 (7.4) 14 (11.5) 8 (6.6) 16 (13.1) 21 (17.2) 122 (12.0)
AHDSS outcome (P , 0.001)
Still in HDSS 17 (3.4) 177 (35.0) 52 (10.3) 7 (1.4) 141 (27.9) 111 (22.0) 0 (0) 505 (49.7)
Deceased 70 (94.6) 4 (5.4) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 74 (7.3)
Migrated 22 (8.1) 86 (31.8) 19 (7.0) 34 (12.6) 58 (21.5) 0 (0) 51 (18.9) 270 (26.5)
Not linked 11 (6.5) 48 (28.6) 4 (2.4) 8 (4.8) 26 (15.5) 0 (0) 71 (42.3) 168 (16.5)
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possible that we might have missed some with information on
patients we were trying to find. The observational nature of
the study limited our ability to assess predictive factors and
causality. We failed to ascertain the outcomes for 12% of our
cohort and this may introduce some downward bias to our
estimates. Finally, as we only resolved cause of death in
48.3% of patients found to have died, this data should be
interpreted with caution. As we attempted to trace all adult
patients LTFU, rather than a sample, these results are likely to
be generalizable to other rural sub-Saharan settings. A
strength of this study is the use of multiple data sources.
In conclusion, our study offers evidence for the growing
utility for routine patient tracing. The different distribution of
outcomes among Option B+ women suggests that different
program mortality and attrition correction factors will be
needed as universal test and treat becomes more established.
Higher mortality among men emphasizes the importance of
programmatic efforts to reach men earlier and treatment
FIGURE 1. Status of patients by
baseline CD4 and years since their
last clinic visit.
FIGURE 2. Status of patients by sex,
pregnancy status at ART initiation,
and years since their last clinic visit.
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TABLE 3. Factors Associated With Death
HR (95% CI) P aHR (95% CI) n = 932 P
Sex
Female Reference __
Male 2.10 (1.57 to 2.81) ,0.001
Age
18–29 Reference __ Reference __
30–44 2.68 (1.30 to 5.51) 0.007 2.37 (0.98 to 5.75) 0.056
45–59 4.73 (3.13 to 7.15) ,0.001 2.96 (1.44 to 6.08) 0.003
60+ 11.31 (5.32 to 24.06) ,0.001 8.86 (3.90 to 20.14) ,0.001
ART reason
Non-PMTCT Reference __ Reference __
PMTCT 0.17 (0.07 to 0.43) ,0.001 0.36 (0.15 to 0.87) 0.022
ART start yr
2014 1.29 (0.82 to 2.04) 0.268
2015 Reference __
2016 1.20 (0.67 to 2.14) 0.536
2017 1.28 (0.83 to 1.97) 0.258
Time on ART
#3 mo Reference __ Reference __
3–6 mo 0.56 (0.31 to 0.99) 0.048 0.76 (0.46 to 1.25) 0.276
6–12 mo 0.74 (0.49 to 1.13) 0.167 0.82 (0.56 to 1.20) 0.307
12–24 mo 0.53 (0.31 to 0.91) 0.023 0.44 (0.23 to 0.85) 0.015
.24 mo 0.91 (0.41 to 2.05) 0.828 0.60 (0.23 to 1.56) 0.297
Baseline CD4
,100 4.26 (3.11 to 5.82) ,0.001 3.77 (2.31 to 6.15) ,0.001
100–199 2.57 (1.60 to 4.12) ,0.001 2.35 (1.49 to 3.69) ,0.001
200–349 Reference __ Reference __
350–499 0.78 (0.39 to 1.55) 0.483 1.11 (0.53 to 2.36) 0.776
500+ 0.82 (0.24 to 2.79) 0.756 1.13 (0.35 to 3.67) 0.840
Baseline WHO stage
I Reference __ Reference __
II 1.71 (0.98 to 3.00) 0.061 0.86 (0.40 to 1.86) 0.706
III 2.70 (1.77 to 4.14) ,0.001 1.36 (0.94 to 1.96) 0.102
IV 6.64 (3.08 to 14.32) ,0.001 3.14 (1.14 to 8.59) 0.026
Refill schedule
1 mo Reference __
2 mo 0.83 (0.37 to 1.86) 0.647
3 mo 0.93 (0.49 to 1.75) 0.824
.3 mo 0.74 (0.22 to 2.42) 0.615
Health facility
Agincourt Reference __ Reference __
Belfast 1.03 (0.97 to 1.09) 0.345 0.80 (0.61 to 1.05) 0.108
Cunningmore 3.14 (2.98 to 3.31) ,0.001 3.39 (2.92 to 3.94) ,0.001
Justicia 2.10 (1.98 to 2.24) ,0.001 1.70 (1.55 to 1.86) ,0.001
Kildare 1.90 (1.84 to 1.95) ,0.001 1.08 (0.78 to 1.50) 0.639
Bhubezi 1.26 (1.19 to 1.34) ,0.001 0.96 (0.73 to 1.28) 0.810
Thulamahashe 0.93 (0.91 to 0.95) ,0.001 1.59 (1.15 to 2.22) 0.005
Xanthia 1.75 (0.70 to 1.80) ,0.001 1.98 (1.64 to 2.38) ,0.001
Time since last appointment
#1 yr Reference __ Reference __
1–2 yrs 1.57 (1.03 to 2.39) 0.037 1.75 (1.10 to 2.78) 0.018
.2 yrs 1.65 (0.73 to 3.75) 0.228 0.81 (0.39 to 1.67) 0.564
All CD4 data was retrieved from clinic records (files and TIER.Net). All other clinical data was retrieved from the PIRL database (sex and age were crosschecked in clinic and
HDSS records).
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programs need to improve transfer procedures to make it more
conducive for patients to move between clinics.
ACKNOWLEDGMENTS
The authors would like to thank all the participants in
the study.
REFERENCES
1. The TEMPRANO ANRS 12136 Study Group. A trial of early
antiretrovirals and isoniazid preventive therapy in Africa. N Engl J
Med. 2015;373:808–822.
2. Group TISS. Initiation of antiretroviral therapy in early asymptomatic
HIV infection. N Engl J Med. 2015;373:795–807.
3. WHO. Guideline on when to Start Antiretroviral Therapy and on Pre-
exposure Prophylaxis for HIV. Geneva, Switzerland: World Health
Organization; 2015.
4. Tymejczyk O, Brazier E, Yiannoutsos CT, et al. Changes in rapid HIV
treatment initiation after national “treat all” policy adoption in 6 sub-
Saharan African countries: regression discontinuity analysis. PLoS Med.
2019;16:e1002822.
5. Boulle A, Van Cutsem G, Hilderbrand K, et al. Seven-year experience of
a primary care antiretroviral treatment programme in Khayelitsha, South
Africa. AIDS Lond Engl. 2010;24:563–572.
6. Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation
of antiretroviral therapy: a systematic review and meta-analysis. AIDS
Lond Engl. 2018;32:17–23.
7. Knettel BA, Cichowitz C, Ngocho JS, et al. Retention in HIV care during
pregnancy and the postpartum period in the option B+ era: a systematic
review and meta-analysis of studies in Africa. JAIDS J Acquir Immune
Defic Syndr. 2017;77:427–438.
8. Tweya H, Gareta D, Chagwera F, et al. Early active follow-up of patients on
antiretroviral therapy (ART) who are lost to follow-up: the “Back-to-Care”
project in Lilongwe, Malawi. Trop Med Int Health. 2010;15(suppl 1):82–89.
9. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral
therapy in clinical practice: a systematic review. Trop Med Int Health.
2011;16:1297–1313.
10. McMahon JH, Elliott JH, Hong SY, et al. Effects of physical tracing on
estimates of loss to follow-up, mortality and retention in low and middle
income country antiretroviral therapy programs: a systematic review.
PLoS One. 2013;8:e56047.
11. WHO. Retention in HIV Programmes: Defining the Challenges and
Identifying Solutions: Meeting Report, 13–15 September 2011. World
Health Organization; 2012. Available at: https://apps.who.int/iris/handle/
10665/44878. Accessed January 21, 2020.
12. Wilkinson LS, Skordis-Worrall J, Ajose O, et al. Self-transfer and
mortality amongst adults lost to follow-up in ART programmes in low-
and middle-income countries: systematic review and meta-analysis. Trop
Med Int Health. 2015;20:365–379.
13. Clouse K, Vermund SH, Maskew M, et al. Mobility and clinic switching
among postpartum women considered lost to HIV care in South Africa. J
Acquir Immune Defic Syndr. 2017;74:383–389.
14. Tweya H, Feldacker C, Estill J, et al. Are they really lost? “true” status
and reasons for treatment discontinuation among HIV infected patients
on antiretroviral therapy considered lost to follow up in Urban Malawi.
PLoS One. 2013;8:e75761.
15. Zürcher K, Mooser A, Anderegg N, et al. Outcomes of HIV-positive
patients lost to follow-up in African treatment programmes. Trop Med Int
Health 2017;22:375–387.
16. Geng EH, Bangsberg DR, Musinguzi N, et al. Understanding reasons for
and outcomes of patients lost to follow-up in antiretroviral therapy
programs in Africa through a sampling-based approach. J Acquir Immune
Defic Syndr. 2010;53:405–411.
17. Stover J, Johnson P, Hallett T, et al. The Spectrum projection package:
improvements in estimating incidence by age and sex, mother-to-child
transmission, HIV progression in children and double orphans. Sex
Transm Infect. 2010;86(suppl 2):ii16–ii21.
18. Brinkhof MWG, Pujades-Rodriguez M, Egger M. Mortality of patients
lost to follow-up in antiretroviral treatment programmes in resource-
limited settings: systematic review and meta-analysis. PLoS One. 2009;4:
e5790.
19. Hoffman S, Wu Y, Lahuerta M, et al. Advanced disease at enrollment in
HIV care in four sub-Saharan African countries: change from 2006 to
2011 and multilevel predictors in 2011. AIDS Lond Engl. 2014;28:
2429–2438.
20. Tweya H, Gugsa S, Hosseinipour M, et al. Understanding factors,
outcomes and reasons for loss to follow-up among women in Option B+
PMTCT programme in Lilongwe, Malawi. Trop Med Int Health. 2014;
19:1360–1366.
21. Osler M, Hilderbrand K, Goemaere E, et al. The continuing burden of
advanced HIV disease over 10 Years of increasing antiretroviral therapy
coverage in South Africa. Clin Infect Dis. 2018;66(suppl_2):S118–S125.
22. Nachega JB, Uthman OA, Anderson J, et al. Adherence to antiretroviral
therapy during and after pregnancy in low-income, middle-income, and
high-income countries: a systematic review and meta-analysis. AIDS
Lond Engl. 2012;26:2039–2052.
23. Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of
adult patients lost to follow-up at an antiretroviral treatment clinic in
johannesburg, South Africa. J Acquir Immune Defic Syndr. 2008;47:
101–107.
24. Dow A, Dube Q, Pence BW, et al. Postpartum depression and HIV
infection among women in Malawi. J Acquir Immune Defic Syndr. 2014;
65:359–365.
25. van Lettow M, Bedell R, Mayuni I, et al. Towards elimination of mother-
to-child transmission of HIV: performance of different models of care for
initiating lifelong antiretroviral therapy for pregnant women in Malawi
(Option B+). J Int AIDS Soc. 2014;17:18994.
26. Clouse K, Schwartz S, Van Rie A, et al. What they wanted was to give
birth; nothing else: barriers to retention in option B+ HIV care among
postpartum women in South Africa. J Acquir Immune Defic Syndr. 2014;
67:e12–18.
27. Hayes R, Donnell D, Floyd S, et al. PopART Study Team. Impact of
Universal Testing and Treatment in Zambia and South Africa: HPTN071
(PopART). Seattle, WA; 2019. Available at: http://www.croiconference.
org/sites/default/files/uploads/92LB.pdf. Accessed May 16, 2019.
28. Dabis F; TasP study group. The Impact of Universal Test and Treat on HIV
Incidence in a Rural South African Population: ANRS 12249 TasP Trial,
2012–2016. Durban, South Africa; 2016. Available at: http://programme.
aids2016.org/Abstract/Abstract/10537. Accessed May 16, 2019.
29. Havlir D; SEARCH collaboration. SEARCH Community Cluster Ran-
domized Study of HIV “Test and Treat” Using Multi- Disease Approach
and Streamlined Care in Rural Uganda and Kenya. Amsterdam,
Netherlands; 2018. Available at: https://programme.aids2018.org/
Abstract/Abstract/13469. Accessed May 16, 2019.
30. Kahn K, Collinson MA, Gómez-Olivé FX, et al. Profile: Agincourt health
and socio-demographic surveillance system. Int J Epidemiol. 2012;41:
988–1001.
31. Tollman SM, Herbst K, Garenne M, et al. The Agincourt demographic
and health study—site description, baseline findings and implications. S
Afr Med J. 1999;89:858–864.
32. Gómez-Olivé FX, Angotti N, Houle B, et al. Prevalence of HIV among
those 15 and older in rural South Africa. AIDS Care. 2013;25:
1122–1128.
33. Byass P, Hussain-Alkhateeb L, D’Ambruoso L, et al. An integrated
approach to processing WHO-2016 verbal autopsy data: the InterVA-5
model. BMC Med. 2019;17:102.
34. WHOjICD-10 Online Versions. WHO. Available at: http://www.who.int/
classifications/icd/icdonlineversions/en/. Accessed April 20, 2020.
35. Kahn K, Tollman SM, Garenne M, et al. Validation and application of
verbal autopsies in a rural area of South Africa. Trop Med Int Health.
2000;5:824–831.
36. Byass P, Calvert C, Miiro-Nakiyingi J, et al. InterVA-4 as a public health
tool for measuring HIV/AIDS mortality: a validation study from five
African countries. Glob Health Action. 2013;6:22448.
37. South Africa: National Department of Health. Adherence Guidelines for
HIV, TB and NCDs: Policy and Service Delivery Guidelines for Linkage
to Care, Adherence to Treatment and Retention in Care. 2016. Available
at: http://www.differentiatedservicedelivery.org/Portals/0/adam/Content/
3QvfVVZSK0G1PlKvq1vTVw/File/15%202%2016%20AGL%20policy
%20and%20service%20delivery%20guidelines.pdf. Accessed March 8,
2018.
Etoori et al J Acquir Immune Defic Syndr  Volume 85, Number 2, October 1, 2020
136 | www.jaids.com Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
38. Rentsch CT, Kabudula CW, Catlett J, et al. Point-of-contact Interactive
Record Linkage (PIRL): a software tool to prospectively link demo-
graphic surveillance and health facility data. Gates Open Res. 2018;1:8.
39. Osler M, Hilderbrand K, Hennessey C, et al. A three-tier framework for
monitoring antiretroviral therapy in high HIV burden settings. J Int AIDS
Soc. 2014;17:18908.
40. MacPherson P, Moshabela M, Martinson N, et al. Mortality and loss to
follow-up among HAART initiators in rural South Africa. Trans R Soc
Trop Med Hyg. 2009;103:588–593.
41. Cornell M, Lessells R, Fox MP, et al. Mortality among adults transferred and
lost to follow-up from antiretroviral therapy programmes in South Africa:
a multicenter cohort study. J Acquir Immune Defic Syndr. 2014;67:e67–75.
42. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults
accessing antiretroviral treatment programmes in sub-Saharan Africa.
AIDS. 2008;22:1897–1908.
43. StataCorp. Stata Statistical Software. College Station, TX: StataCorp
LLC; 2017.
44. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline
CD4 cell count and viral load after initiating triple-drug therapy. JAMA.
2001;286:2568–2577.
45. Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients
on potent antiretroviral therapy programmes in lower-income countries.
Bull World Health Organ. 2008;86:559–567.
46. Garenne M, Kahn K, Collinson MA, et al. Maternal mortality in rural
South Africa: the impact of case definition on levels and trends. Int J
Womens Health. 2013;5:457–463.
47. Garenne M, Kahn K, Collinson M, et al. Protective effect of pregnancy in
rural South Africa: questioning the concept of indirect cause of maternal
death. PLoS One. 2013;8:e64414.
48. Heffron R, Donnell D, Kiarie J, et al. A prospective study of the effect of
pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of
antiretroviral-naive HIV-1 infected women. J Acquir Immune Defic
Syndr. 2014;65:231–236.
49. Meyer-Rath G, Johnson LF, Pillay Y, et al. Changing the South African
national antiretroviral therapy guidelines: the role of cost modelling.
PLoS One. 2017;12:e0186557.
50. South Africa: National Department of Health. Implementation of the
Universal Test and Treat Strategy for HIV Positive Patients and
Differentiated Care for Stable Patients. 2016. Available at: https://
sahivsoc.org/Files/22%208%2016%20Circular%20UTT%20%20%
20Decongestion%20CCMT%20Directorate.pdf. Accessed July 24,
2019.
51. South Africa: National Department of Health. National Consolidated
Guidelines for the Prevention of Mother-To-Child Transmission of HIV
(PMTCT) and the Management of HIV in Children, Adolescents and
Adults. 2015. Available at: https://www.scribd.com/doc/268965647/
National-Consolidated-Guidelines-for-PMTCT-and-the-Management-of-
HIV-in-Children-Adolescents-and-Adults. Accessed July 24, 2019.
52. Cornell M, Schomaker M, Garone DB, et al. Gender differences in
survival among adult patients starting antiretroviral therapy in South
Africa: a multicentre cohort study. PLoS Med. 2012;9:e1001304.
53. Braitstein P, Boulle A, Nash D, et al. Gender and the use of antiretroviral
treatment in resource-constrained settings: findings from a multicenter
collaboration. J Womens Health. 2008;17:47–55.
54. Stringer JSA, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral
therapy at primary care sites in Zambia: feasibility and early outcomes.
JAMA. 2006;296:782–793.
55. Cornell M, Grimsrud A, Fairall L, et al. Temporal changes in programme
outcomes among adult patients initiating antiretroviral therapy across South
Africa, 2002–2007. AIDS Lond Engl. 2010;24:2263–2270.
56. Mills EJ, Beyrer C, Birungi J, et al. Engaging men in prevention and care
for HIV/AIDS in Africa. PLoS Med. 2012;9:e1001167.
57. Katirayi L, Chadambuka A, Muchedzi A, et al. Echoes of old HIV
paradigms: reassessing the problem of engaging men in HIV testing and
treatment through women’s perspectives. Reprod Health 2017;14:124.
58. Pulerwitz J, Michaelis A, Verma R, et al. Addressing gender dynamics
and engaging men in HIV programs: lessons learned from horizons
research. Public Health Rep. 2010;125:282–292.
59. Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-
infected patients in resource-limited settings: emerging insights and new
directions. Curr HIV/AIDS Rep. 2010;7:234–244.
60. Nglazi MD, Kaplan R, Orrell C, et al. Increasing transfers-out from an
antiretroviral treatment service in South Africa: patient characteristics
and rates of virological non-suppression. PLoS One. 2013;8:e57907.
61. Wang B, Losina E, Stark R, et al. Loss to follow-up in a community
clinic in South Africa—roles of gender, pregnancy and CD4 count. S Afr
Med J. 2011;101:253–257.
62. Ferguson L, Lewis J, Grant AD, et al. Patient attrition between diagnosis
with HIV in pregnancy-related services and long-term HIV care and
treatment services in Kenya: a retrospective study. J Acquir Immune
Defic Syndr. 2012;60:e90–97.
63. Castro H, Pillay D, Sabin C, et al. UK Collaborative Group on HIV Drug
Resistance. Effect of misclassification of antiretroviral treatment status on
the prevalence of transmitted HIV-1 drug resistance. BMC Med Res
Methodol. 2012;12:30.
64. Egger M, Spycher BD, Sidle J, et al. Correcting mortality for loss to
follow-up: a nomogram applied to antiretroviral treatment programmes in
sub-Saharan Africa. PLoS Med. 2011;8:e1000390.
65. Katirayi L, Chouraya C, Kudiabor K, et al. Lessons learned from the
PMTCT program in Swaziland: challenges with accepting lifelong ART
for pregnant and lactating women—a qualitative study. BMC Public
Health 2016;16:1119.
66. Kim MH, Zhou A, Mazenga A, et al. Why did I stop? Barriers and
facilitators to uptake and adherence to ART in option B+ HIV care in
lilongwe, Malawi. PLoS One. 2016;11:e0149527.
67. Fox MP, Brennan A, Maskew M, et al. Using vital registration data to
update mortality among patients lost to follow-up from ART programs:
evidence from the themba lethu clinic, South Africa. Trop Med Int
Health. 2010;15:405–413.
68. Van Cutsem G, Ford N, Hildebrand K, et al. Correcting for mortality
among patients lost to follow up on antiretroviral therapy in South Africa:
a cohort analysis. PLoS One. 2011;6:e14684.
HIV Treatment Outcomes Following Loss to Follow-upJ Acquir Immune Defic Syndr  Volume 85, Number 2, October 1, 2020
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. www.jaids.com | 137
